SCHEMBL20206181

SCHEMBL20206181

CC(=O)NCC(=O)N[C@H]1CCC(=O)NCC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCCN)NC1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 7/20 0.41
▸ SIRT1 Q96EB6 7/20 0.41
▸ SIRT3 Q9NTG7 7/20 0.41
▸ SSTR1 P30872 1/20 0.41
▸ SSTR2 P30874 1/20 0.41
▸ SSTR4 P31391 1/20 0.41
▸ SSTR3 P32745 1/20 0.41
▸ SSTR5 P35346 1/20 0.41
▸ KLKB1 P03952 1/20 0.41
▸ PLAU P00749 1/20 0.41
▸ MC4R P32245 1/20 0.40
▸ TBXA2R P21731 1/20 0.40
▸ AVPR1A P37288 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ PDE3A Q14432 1/20 0.40
▸ SLC6A2 P23975 1/20 0.39
▸ ITGB3 P05106 1/20 0.39
▸ ITGAV P06756 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20206177 0.98 MC4R (0.40) SIRT2SIRT1SIRT3SSTR1SSTR2
SCHEMBL20206207 0.95 KEAP1 (0.40) SIRT2SIRT1SIRT3MC4RTBXA2R
SCHEMBL20206279 0.93 SIRT2 (0.42) SIRT2SIRT1SIRT3KLKB1MC4R
SCHEMBL20206246 0.92 CTSG (0.46) SIRT2SIRT1SIRT3KLKB1PLAU
SCHEMBL20206174 0.91 OPRM1 (0.44) —
SCHEMBL20206278 0.90 MEN1 (0.40) MC4R
SCHEMBL20206173 0.86 TSLP (0.39) MC4R
SCHEMBL20206244 0.84 MC4R (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL21392264 0.84 MC4R (0.57) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL20362936 0.84 TSLP (0.39) MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy PALATIN TECHNOLOGIES, INC. (US) 2022-03-29 — — US disclosed
US-20200339631-A1 Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy PALATIN TECHNOLOGIES INC (US) 2020-10-29 — — US disclosed
US-10711039-B2 Melanocortin receptor-specific peptide with C-terminal naphthylalanine PALATIN TECHNOLOGIES, INC. (US) 2020-07-14 — — US disclosed
US-10017539-B2 Melanocortin-1 receptor-specific cyclic hexapeptides PALATIN TECHNOLOGIES, INC. (US) 2018-07-10 — — US disclosed
US-20180148478-A1 Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine PALATIN TECHNOLOGIES INC (US) 2018-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711039-B2 Melanocortin receptor-specific peptide with C-terminal naphthylalanine MC1R, MC3R, MC4R SIRT2 3928/4885SIRT1 3176/4885SIRT3 2985/4885
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy MC3R, MC1R, MC2R SIRT2 3491/4885SIRT1 2810/4885SIRT3 3692/4885
US-10017539-B2 Melanocortin-1 receptor-specific cyclic hexapeptides MC1R, MC3R, MC5R SIRT2 3664/4885SIRT1 1974/4885SIRT3 2283/4885
US-20200339631-A1 Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy MC3R, MC1R, MC2R SIRT2 3491/4885SIRT1 2810/4885SIRT3 3692/4885
US-20180148478-A1 Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine MC1R, MC3R, MC4R SIRT2 3928/4885SIRT1 3176/4885SIRT3 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback